Oxford BioMedica logo

OXB - Oxford BioMedica News Story

1024p -18.0  -1.7%

Last Trade - 07/05/21

Sector
Healthcare
Size
Mid Cap
Market Cap £844.0m
Enterprise Value £811.1m
Revenue £87.7m
Position in Universe 475th / 1821

BRIEF-Oxford BioMedica FY Operating Loss 5.7 Million Stg

Thu 15th April, 2021 7:18am
April 15 (Reuters) - Oxford BioMedica PLC  OXB.L :
    * FY LOSS -6.2 MILLION STG
    * FY OPERATING EBITDA 7.3 MILLION STG VERSUS -5.2 MILLION
STG LOSS
YEAR AGO
    * FY OPERATING LOSS -5.7 MILLION STG VERSUS -14.5 MILLION
STG LOSS
YEAR AGO
    * FY TOTAL REVENUES INCREASED BY 37% TO £87.7 MILLION
    * OXFORD BIOMEDICA - SEES INCREASE IN UNDERLYING
LENTIVECTOR(®)
PLATFORM BASED REVENUE IN 2021 FROM BOTH BIOPROCESSING AND
COMMERCIAL DEVELOPMENT ACTIVITIES
    * SEES TOTAL CUMULATIVE REVENUES FROM ASTRAZENECA VACCINE
PROGRAMME TO BE IN EXCESS OF £50 MILLION BY END OF 2021
    * AT AN OPERATING EBITDA LEVEL, GROUP ALSO EXPECTS AN
INCREASE
FROM 2020
    * RESEARCH AND DEVELOPMENT EXPENDITURE IN 2021 IS EXPECTED
TO BE
ABOVE £29.7 MILLION SEEN IN 2020
    * CAPEX FOR 2021 WILL BE ABOVE 2020

Source text for Eikon:  ID:nRSO5632Va 
Further company coverage:  OXB.L 

 ((Reuters.Briefs@thomsonreuters.com;))
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.